Value through Innovation27 July 2016

Clinical Study Results

  • BI 44370 - Migraine Disorders
    Clinical Study Number 1246.4
    Study Indication Migraine Disorders
    Product BI 44370
    Generic Name BI 44370
    Lab Code
    Clinical Phase I
    Study Title

    A randomised, double-blind, placebo- and active comparator-controlled, five parallel groups study to investigate the efficacy and safety of BI 44370 TA (50 mg, 200 mg, and 400 mg) administered orally once during an acute migraine attack of moderate or severe intensity

    Study Document Trial synopsis 1246.4 english
  • BI 44370 - Migraine Disorders
    Clinical Study Number 1246.21
    Study Indication Migraine Disorders
    Product BI 44370
    Generic Name BI 44370
    Lab Code
    Clinical Phase I
    Study Title

    Relative bioavailability following single oral administration of 200 mg of BI 44370 during and between migraine attacks in male and female migraine patients. An open-label, fixed-sequence, two-period study with intraindividual comparison

    Study Document Trial synopsis 1246.21 english
  • LISAGIL ® - Migraine Disorders
    Clinical Study Number 1093.16
    Study Indication Migraine Disorders
    Product LISAGIL ®
    Generic Name Metamizole
    Lab Code
    Clinical Phase III
    Study Title

    A randomised, double blind, placebo- and active-controlled parallel group study investigating the efficacy and tolerability of metamizol 0.5 g and 1.0 g in patients with episodic moderate tension headache.

    Study Document Trial synopsis 1093.16 english
  • Olcegepant - Migraine Disorders
    Clinical Study Number 1149.2
    Study Indication Migraine Disorders
    Product Olcegepant
    Generic Name Olcegepant
    Lab Code
    Clinical Phase IIa
    Study Title

    A Phase IIa, double Blind, Ransomised, Group Sequential Adaptive Assignment Desing Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of seven Fixed Doses of Intravenous BIBN 4096 BS ranging from 0.1 to 10.0 mg Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache.

    Study Document Trial synopsis 1149.2_CO english
  • THOMAPYRIN S® - Migraine Disorders
    Clinical Study Number 155.8
    Study Indication Migraine Disorders
    Product THOMAPYRIN S®
    Generic Name Paracetamol + Acetylsalicylic acid
    Lab Code
    Clinical Phase III
    Study Title

    A double-blind, randomized, placebo-controlled clinical trial to confirm the rationale of the ASA + paracetamol + caffeine combination compared with ASA + paracetamol as well as ASA, paracetamol and caffeine in headache patients

    Study Document Trial synopsis 155.8 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.